134 related articles for article (PubMed ID: 24452953)
1. Effects of chemotherapy on global gene expression in non-small cell lung cancer.
Li J; Shi R; Yu P
Eur Rev Med Pharmacol Sci; 2014; 18(1):126-31. PubMed ID: 24452953
[TBL] [Abstract][Full Text] [Related]
2. Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.
Ma GF; Zhang RF; Ying KJ; Wang D
Eur Rev Med Pharmacol Sci; 2015 Feb; 19(4):578-85. PubMed ID: 25753874
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of circPVT1 in patients with non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy.
Lu H; Xie X; Chen Q; Cai S; Liu S; Bao C; Luo J; Kong J
Tumori; 2021 Jun; 107(3):204-208. PubMed ID: 32734834
[TBL] [Abstract][Full Text] [Related]
6. GOLM1 predicts poor prognosis of patients with NSCLC and is associated with the proliferation and chemo-sensitivity of cisplatin in NSCLC cells: bioinformatics analysis and laboratory validation.
Zhao M; Li X; Chen X
J Bioenerg Biomembr; 2021 Apr; 53(2):177-189. PubMed ID: 33538941
[TBL] [Abstract][Full Text] [Related]
7. Identification of miRNAs and differentially expressed genes in early phase non-small cell lung cancer.
Tian W; Liu J; Pei B; Wang X; Guo Y; Yuan L
Oncol Rep; 2016 Apr; 35(4):2171-6. PubMed ID: 26781349
[TBL] [Abstract][Full Text] [Related]
8. Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy.
Xin XL; Wang GD; Han R; Jiang Y; Liu C; Liu LS; Xu ZY
J Tradit Chin Med; 2022 Feb; 42(1):108-115. PubMed ID: 35294130
[TBL] [Abstract][Full Text] [Related]
9. [Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].
Chen Y; Qian X; Liu B
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):421-8. PubMed ID: 21569648
[TBL] [Abstract][Full Text] [Related]
10. Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.
Chen YC; Hsiao CC; Chen KD; Hung YC; Wu CY; Lie CH; Liu SF; Sung MT; Chen CJ; Wang TY; Chang JC; Tang P; Fang WF; Wang YH; Chung YH; Chao TY; Leung SY; Su MC; Wang CC; Lin MC
PLoS One; 2013; 8(2):e57053. PubMed ID: 23451142
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Potential Mechanisms Associated with Non-small Cell Lung Cancer.
Shi Y; Zhu S; Yang J; Shao M; Ding W; Jiang W; Sun X; Yao N
J Comput Biol; 2020 Sep; 27(9):1433-1442. PubMed ID: 32048869
[TBL] [Abstract][Full Text] [Related]
12. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.
Samakoglu S; Deevi DS; Li H; Wang S; Murphy M; Bao C; Bassi R; Prewett M; Tonra JR
Cancer Genomics Proteomics; 2012; 9(2):77-92. PubMed ID: 22399498
[TBL] [Abstract][Full Text] [Related]
13. CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy.
Goldmann T; Drömann D; Radtke J; Marwitz S; Lang DS; Schultz H; Vollmer E
Virchows Arch; 2008 Mar; 452(3):347-8. PubMed ID: 18214534
[No Abstract] [Full Text] [Related]
14. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
15. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
16. MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
Lu M; Hu C; Wu F; Shu L; Pan Y; Liu X; Liu P; Ma F; Deng C; Huang M
Lung Cancer; 2020 Sep; 147():193-197. PubMed ID: 32731058
[TBL] [Abstract][Full Text] [Related]
17. Identification and Integrated Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer.
Liu X; Liu X; Li J; Ren F
Med Sci Monit; 2019 Dec; 25():9280-9289. PubMed ID: 31805030
[TBL] [Abstract][Full Text] [Related]
18. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
Tian Y; Zhang J; Yan S; Qiu L; Li Z
Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
[TBL] [Abstract][Full Text] [Related]
19. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Wu YL; Zhou C; Lu S; Qin S; Pan H; Wu G; Cheng Y; Liu X; Han B; Zhu Y; Zhong Z; Huang C; Chen L; Liang H; Li E; Jiang G
Lung Cancer; 2019 Apr; 130():18-24. PubMed ID: 30885342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
